ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0826

Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19

Miao Wang1, Sylvie Lardeux2, Elisea Avalos-Reyes3, Michele Hamburger4 and Kjel Johnson5, 1CVS Health, New York, NY, 2CVS Health, Wellesley, MA, 3CVS Health, Irving, TX, 4Frances Hamburger Institute, Hauppauge, NY, 5CVS Health, Lincoln, RI

Meeting: ACR Convergence 2021

Keywords: Access to care, Cohort Study, COVID-19, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known to be particularly susceptible to infections. During the pandemic, RA patients were found to cancel appointments and alter medications. This study aimed to understand the impact of COVID-19 on RA patients’ diagnosis, treatment, and utilization during the pandemic.

Methods: This is a retrospective cohort study of RA patients insured by a large Commercial and Medicare health plan in the United States. To assess the impact of COVID-19 on newly diagnosed treatment and utilization rates, we compareda pre-COVID period (March 1 to December 31, 2019) to a COVID period (March 1 to December 31, 2020) to assess how COVID-19 impacted changes. We defined a new RA diagnosis as a patient with medical insurance but no paid claim for RA for at least six months before the initial claim with an RA diagnosis. We utilized both medical and pharmacy claims to identify utilization patterns.

Results: This study included 36,019 patients in 2019 and 35,880 patients in 2020. The newly diagnosed rate increased 6% (p = 0.002) for Medicare but not for Commercial patients. Infusion treatments decreased 7% (p=0.03) for Commercial but not for Medicare patients. During this time, there was a switch in infusion site of care from the hospital setting to the office setting of 3.1% (p=0.05) and 5.7% (p< 0.001) for Commercial and Medicare patients, respectively. There was also a switch from facility to office-based biologic drug administration for Commercial (1.8%, p= 0.03) and Medicare patients (2.6%, p = 0.08). From March to May 2020, there was an 18-19% decrease (p < 0.001) in new RA diagnoses for Commercial and Medicare patients with a rebound in the last six months of 2020. There was an 11-17% decrease (p < 0.001) in utilization among existing patients during this time. Having COVID-19 increased the odds of being newly diagnosed with RA by 1.37 in Medicare patients and 1.91 in Commercial patients (both p < 0.001).

Conclusion: During the COVID-19 pandemic, we observed higher RA incidence rates. Additionally, infusion treatments decreased and changed from the hospital to the office setting. While new RA diagnosis and utilization rates of existing RA patients declined during the pandemic’s height, both rates quickly rebounded in the last months of 2020. As a result, patients treated for COVID-19 were more likely to be newly diagnosed with RA, likely driving the higher incidence rates observed in this study. During the pandemic, some healthcare services were compromised to meet the demands of caring for COVID-19 patients. In some cases, patients canceled appointments or delayed care due to fear of exposure. The results of this study highlight the impact of a pandemic on healthcare.


Disclosures: M. Wang, CVS Health, 3, 11; S. Lardeux, CVS Health, 3, 11; E. Avalos-Reyes, CVS Health, 3, 11; M. Hamburger, None; K. Johnson, CVS Health, 3, 11.

To cite this abstract in AMA style:

Wang M, Lardeux S, Avalos-Reyes E, Hamburger M, Johnson K. Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/diagnosis-treatment-and-utilization-changes-in-rheumatoid-arthritis-patients-before-and-during-covid-19/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnosis-treatment-and-utilization-changes-in-rheumatoid-arthritis-patients-before-and-during-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences